Diversity considerations in HIV-1 vaccine selection.

Published

Journal Article (Review)

Globally, human immunodeficiency virus-type 1 (HIV-1) is extraordinarily variable, and this diversity poses a major obstacle to AIDS vaccine development. Currently, candidate vaccines are derived from isolates, with the hope that they will be sufficiently cross-reactive to protect against circulating viruses. This may be overly optimistic, however, given that HIV-1 envelope proteins can differ in more than 30% of their amino acids. To contend with the diversity, country-specific vaccines are being considered, but evolutionary relationships may be more useful than regional considerations. Consensus or ancestor sequences could be used in vaccine design to minimize the genetic differences between vaccine strains and contemporary isolates, effectively reducing the extent of diversity by half.

Full Text

Duke Authors

Cited Authors

  • Gaschen, B; Taylor, J; Yusim, K; Foley, B; Gao, F; Lang, D; Novitsky, V; Haynes, B; Hahn, BH; Bhattacharya, T; Korber, B

Published Date

  • June 28, 2002

Published In

Volume / Issue

  • 296 / 5577

Start / End Page

  • 2354 - 2360

PubMed ID

  • 12089434

Pubmed Central ID

  • 12089434

Electronic International Standard Serial Number (EISSN)

  • 1095-9203

Digital Object Identifier (DOI)

  • 10.1126/science.1070441

Language

  • eng

Conference Location

  • United States